Phase 2 N=175 Preventing Diabetic Foot Ulcers Through Cleaner Feet
Diabetic Foot Ulcer
Primary: Time to New Foot Complication Among All Randomized Participants — 12; 14 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 Micro-mobile Foot Compression and Diabetic Foot
Diabetes · PAD · Lower Extremity Edema
Primary: Change in Balance From Baseline to 4 Weeks — 0.94; 0.76 cm
Phase 3 N=68 Efficacy of the Combination of Isosorbide Dinitrate Spray and Chitosan in Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Biopsies — 2.46; 2.64; 2.56; 2.07 UI/dL
N/A N=99 Enhancing Diabetic Foot Education by Viewing Personal Plantar Pressures
Diabetes Mellitus · Diabetic Neuropathies · Foot Complications
Primary: Foot Care Behavior Score — 29; 36; 33; 42 Participants — p=0.0770
Phase 2 N=16 Novel Offloading for Diabetic Foot Ulcers With PulseFlow: A Prospective Study
Diabetic Foot Ulcer · Offloading
Primary: Lower Extremity Perfusion Change From Baseline to 4 Weeks — 167; 75 percentage of baseline perfusion
N/A N=182 Less Infections for the Diabetic Foot
Diabetic Foot
Primary: Number of Participants Experiencing Clinical Failure — 26; 30 Participants
N/A N=24 Effects of a Exercise Program on Health Outcomes in People With Diabetic Foot Ulcers
Diabetic Foot Ulcer · Diabetes Mellitus, Type 2
Primary: Glycated Hemoglobin (HbA1c) at 12-week Session — 8.0; 7.0 percentage of HbA1c — p=.26
N/A N=41 Neurogenic Inflammation in Diabetes
Diabetes Mellitus · Polyneuropathies · Arthropathy, Neurogenic
Primary: Induration Size as a Response to Intracutaneous Candida Albicans. — 4; 6; 5; 4 millimeters — p=0.84
N/A N=381 Therapeutic Stockings to Prevent Foot Ulcers
Diabetes
Primary: Number of Participants Who Developed Foot Ulcer During Study Time Frame — 76; 82 Participants
Phase 3 N=130 Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Number of 100% Wound Closure — 55.74; 50.82 percentage of patients
N/A N=8 ULCERS - Electrical Stimulation in Diabetic Foot Ulceration
Diabetes
Primary: Number of Day Until 50% Healing of Leg Ulcer — 55; 30 Days
N/A N=24 Extracorporeal Shockwave Therapy for Diabetic Foot Wounds
Diabetic Foot · Wound
Primary: Wound Volume — 1.16 cm^3
N/A N=20 CO2-Laser Treatment in Patients With Diabetic Infected Foot Ulcers
Diabetic Foot Ulcer
Primary: Bacterial Load — -99.9; -50.0 Percent change from baseline
N/A N=12 A Non-significant Risk Clinical Study of Therapeutic Ultrasound for Patients With Diabetic Foot Ulcers.
Diabetic Foot Ulcer · Peripheral Arterial Disease · Wound; Foot
Primary: Transcutaneous Oxygen Pressure (TcPO2) — 50.96 mmHg
Phase 2 N=20 Efficacy of Teriparatide in Diabetic Inactive Charcot Neuroarthropathy of Foot
Diabetic Neuropathic Arthropathy
Primary: SUV Max on PET/CT Scan at 12 Months — 26.1; 22.9 g/ml
Phase 2 N=80 Herbal Preparation Used as Adjuvant Therapy on Diabetic Ulcers
Diabetic Foot Ulcer · Amputation
Primary: Number of Participants With Limb Salvage — 37; 31 Participants
N/A N=604 Diagnostic Tools to Establish the Presence and Severity of Peripheral Arterial Disease in People With Diabetes
Diabetic Foot · Peripheral Arterial Disease · Diabetic Foot Ulcer
Primary: Diagnostic Accuracy — 36; 42; 55; 41 percentage
N/A N=20 Improving DFU Outcomes: Early Detection of Foot Ulcers Using Novel Technology
Diabetic Foot Ulcer
Primary: Adherence to Use of SmartMat — 6.4 number of foot scans/week
Phase 2 N=38 Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections
Diabetic Foot Infections
Primary: Clinical Success (in ITT Population) — 95.7 percentage of participants
N/A N=91 Intensive Insulin Treatment and Ischemic Foot Ulcer
Ischemic Foot Ulcer
Primary: Ischemic Foot Ulcer — 3; 10 participants
N/A N=132 In-Home Assessment of a Smart Foot Mat for Prevention of Diabetic Foot Ulcers
Foot Ulcer, Diabetic
Primary: Occurrence of Plantar Diabetic Foot Ulcer — 37 Participants
N/A N=78 Effects of Foot Muscle Strengthening in Daily Activity in Diabetic Neuropathic Patients
Diabetic Neuropathies
Primary: Daily Physical Activity — 8744; 7373 number of steps per week
N/A N=148 Bioresorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers
Diabetic Foot Ulcer · Ulcer Foot · Diabetic Foot
Primary: Complete Wound Healing — 32; 16; 32; 16 Participants — p=0.007
Phase 4 N=106 DPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 Diabetes
Chronic Foot Ulcers
Primary: Full Epithelialization of the Wound — 16; 8 participants — p=<0.05
N/A N=23 Continuous Diffusion of Oxygen (CDO) Treatment for Healing of Diabetic Foot Ulcers
Foot Ulcer, Diabetic
Primary: Tissue Oxygenation as Measured by Hyperspectral Imaging — 63.58; 61.91; 76.33; 77.55 percent concentration of oxyhemoglobin
Phase 3 N=276 Study Of The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients
Diabetic Foot Ulcer
Primary: Number of Participants With Greater Than or Equal to 50 Percent Reduction in Ulcer Surface Area Including Intact Skin Healing — 68; 31; 23; 14 participants
N/A N=39 Acellular Porcine Dermal Matrix Wound Dressing in the Management of Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Size of Index Wound Based on Calculations Wound Width x Length x Depth 2. Size of Index Wound Based on Calculations Wound Width x Length x Depth — 2.05; 3.33 mm^3
N/A N=225 Instant Total Contact Cast to Heal Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Number of Participants Who Achieve Full Wound Healing. — 35; 63; 37 Participants
Phase 3 N=48 Beta Adrenergic Antagonist for the Healing of Chronic DFU
Chronic Diabetic Foot Ulcers · Diabetic Neuropathic Ulcers · Non Healing Wound
Primary: Percentage of Complete Wound Closure, as Assessed Over a 12 Week Period — 8; 7 Participants
Phase 2 N=124 CSTC1 for Diabetic Foot Ulcers Phase II Study
Diabetic Foot Ulcer · Diabetes Mellitus · Wounds
Primary: Number of Participants With Complete Ulcer Closure During the Treatment Period — 32; 4 Participants